

## Assessment of Clinical Profile of Multi Drug Resistant Tuberculosis Patients: An Institutional Based Study

Sanjay N. Murudkar<sup>1</sup>, Ramesh Yeshwant Wagh<sup>2\*</sup>

<sup>1</sup>Assistant Professor, Department of Pulmonary Medicine, Navodaya Medical College Hospital & Research Centre, Navodaya Nagar, Raichur, Karnataka, India.

<sup>2</sup>Professor, Department of Community Medicine, Chennai Medical college Hospital & Research Centre, Irungalur, Tiruchirapalli, Trichy, Tamil Nadu, India.

### Article History

Received: 07 July 2015

Revised: 25 July 2015

Accepted: 19 Aug 2015

### \*Correspondence to:

Dr. Ramesh Y Wagh,  
Professor, Department  
of Community  
Medicine, Chennai  
Medical college  
Hospital & Research  
Centre, Irungalur,  
Tiruchirapalli, Trichy,  
Tamil Nadu, India.

### ABSTRACT

**Background:** Drug-resistant tuberculosis (DR-TB) has become a significant public health problem in number of countries and one of the major obstacles in effective tuberculosis control programme. The present study was conducted to assess clinical profile of multi drug resistant tuberculosis patients.

**Materials & Methods:** 82 patients of drug resistant TB of both genders were included, and all were subjected to chest X-ray and mantoux test. Assessment of clinical features, type and treatment outcome was recorded.

**Results:** Out of 82 patients, males were 52 and females were 30. Clinical features were fever in 69, cough in 56, loss of appetite in 28, loss of weight in 14 and past history in 6. Type of drug resistance was contact with partial XDR in 10, MDR in 6, MDR with contact in 30 and partial XDR in 36 patients. Type of tuberculosis was pulmonary TB in 40, disseminated TB in 26, TB lymphadenopathy in 9 and abdominal TB in 7 cases. The difference was significant ( $P < 0.05$ ).

**Conclusion:** Common clinical features were fever, cough, loss of appetite and loss of weight.

**KEYWORDS:** Multi Drug Resistant Tuberculosis, Fever, Cough.

### INTRODUCTION

Drug-resistant tuberculosis (DR-TB) has become a significant public health problem in number of countries and one of the major obstacles in effective tuberculosis control programme.<sup>1</sup> Emergence of drug resistant tuberculosis (TB), particularly multi drug resistant tuberculosis (MDR-TB) has been an area of growing concern and is posing a threat to global efforts of TB control.<sup>2</sup> In 2013, there were an estimated 600 000 new cases of MDR-TB worldwide, and approximately 240 000 deaths from MDR-TB with most cases and deaths occurred in Asia.<sup>3</sup> Programmatic management of drug-resistant TB (PMDT) is being implemented in India in a phased manner since 2006. Latest Surveillance shows that 4.1% of new and 19% of previously treated TB cases in the world is estimated to have rifampicin or multidrug-resistant tuberculosis (MDR/RR-TB).<sup>4</sup>

Paediatric tuberculosis can act as sentinels of DRTB it is an aftermath of adult TB. Paediatric DRTB is a silent epidemic which is often overlooked and the cases which present to us may just be the tip of an iceberg. Burden of

DRTB and its clinical profile in paediatric population is inadequately scrutinized.<sup>5</sup> The diagnosis in this age group may be an uphill task due to various hurdles like difficulty in history taking, complex examination findings and difficulty in procurement of sample for an accurate microbiological diagnosis.<sup>6</sup> The therapy of DR-TB in children can be quite wearisome due to quandaries with the dose adjustment modes of drug dispensation and the therapy related ADRs.<sup>7</sup> Hence; under the light of above mentioned data, the present study was conducted to assessing clinical profile of multi drug resistant tuberculosis patients.

### MATERIALS & METHODS

The present study was conducted in the Department of Pulmonary Medicine, Navodaya Medical College Hospital & Research Centre, Navodaya Nagar, Raichur, Karnataka (India) with the aim of assessing clinical profile of multi drug resistant tuberculosis patients. The present study comprised of 82 patients of drug resistant

TB of both genders. Enrolment in the study was done after their parent agreed to give consent. Data such as name, age, gender etc. was recorded. They were defined drug resistant -TB if their drug susceptibility testing (DST) detected resistance to any of the antitubercular drugs, or these children were in contact with an adult suffering from culture proven drug resistance. Patients were classified to have mono resistant TB, polyresistant

TB, MDR TB and XDR-TB as per WHO classification. A history and clinical examination were done in all patients. All were subjected to chest X-ray and mantoux test. Assessment of clinical features, type and treatment outcome was recorded.

Results thus obtained were subjected to statistical analysis. P value less than 0.05 was considered significant.


**Table I: Distribution of patients**

Total- 82		
Gender	Males	Females
Number	52	30

**Table II: Assessment of parameters**

Parameters	Variables	Number	P value
Clinical profile	Fever	69	0.04
	Cough	56	
	Loss of appetite	28	
	Loss of weight	14	
	Past history	6	
Type of drug resistance	Contact with Partial XDR	10	0.01
	MDR	6	
	MDR with contact	30	
	Partial XDR	36	
Type of TB	Pulmonary TB	40	0.02
	Disseminated TB	26	
	TB Lymphadenopathy	9	
	Abdominal TB	7	

**Graph I: Assessment of parameters**



## RESULTS

Table I shows that out of 82 patients, males were 52 and females were 30. Table II graph I shows that clinical features were fever in 69, cough in 56, loss of appetite in 28, loss of weight in 14 and past history in 6. Type of drug resistance was contact with partial XDR in 10, MDR in 6, MDR with contact in 30 and partial XDR in 36 patients. Type of tuberculosis was pulmonary TB in 40, disseminated TB in 26, TB lymphadenopathy in 9 and abdominal TB in 7 cases. The difference was significant ( $P < 0.05$ ).

## DISCUSSION

In India DRTB has been perpetually identified ever since the inception and implementation of the revised national tuberculosis control program (RNTCP).<sup>8</sup> The paediatric population is a scapegoat for acquisition of TB as well as DRTB.<sup>9</sup> Despite of the advances in the diagnostics and the amended therapy protocols TB still continues to prevail as one of the ten major causes of mortality in the paediatric age group.<sup>10</sup> Incidence of Paediatric DR-TB has seldom been estimated precisely although they constitute more than a quarter of the global population. The situation is quite bloodcurdling with the 2016 statistics which estimated 1 million children being afflicted with TB and 250,000 children succumbing to TB.<sup>11</sup> The present study was conducted to assess clinical profile of multi drug resistant tuberculosis patients.

In present study, out of 82 patients, males were 52 and females were 30. We found that clinical features were fever in 69, cough in 56, loss of appetite in 28, loss of weight in 14 and past history in 6. Prasad et al<sup>12</sup> analysed the clinical profile and treatment outcome of DRTB in paediatric population. Out of 120 patients, 95% (114) were above 12 years and rest 5% (6) were below 12 years, male to female ratio was 1:2.53. MDR-TB was present in 85% (102), 9.17% (11) had pre-XDR-TB, 5.83% (7) had XDR-TB. Pulmonary-DRTB was seen in 89.17% (105), 10.83% (15) had extrapulmonary-DRTB. Primary-DRTB was observed in 11.67% (14). Complications noted were pneumothorax (5.83%, 7 cases) and haemoptysis (2.5%, 3 cases). Mean duration of culture conversion was 3.33 months. Commonest adverse drug reactions (ADRs) were Psychosis, gastritis (11.67%, 14 cases each). Overall treatment success was 42.5% (51) which was better in MDR-TB (44.11%, 45 cases) than XDR-TB (28.5%, 2 cases) and Pre-XDR-TB (36.36%, 4 cases). Mortality was 21.67% (26) of whom 19.60% (20) had MDR-TB, 42.8% (3) had XDR-TB, 27.27% (3) had pre-XDR-TB and 20% (24) failed to treatment.

In the present study, type of drug resistance was contact with partial XDR in 10, MDR in 6, MDR with contact in 30 and partial XDR in 36 patients. Type of tuberculosis was pulmonary TB in 40, disseminated TB in 26, TB lymphadenopathy in 9 and abdominal TB in 7 cases.

Shah et al<sup>13</sup> determined the clinical profile of drug-resistant tuberculosis in children. Patients were classified as monoresistant TB, polyresistant TB, multidrug resistant (MDR)-TB and extensively drug resistant (XDR - TB). Of 500 children analysed, 34 (6.8%) had drug resistant TB. Mean age of presentation was  $6.8 \pm 3.2$  years (Male: Female ratio 13:21). 18 (52.9%) children had been treated for tuberculosis in the past (1 defaulted), 7 patients had been in contact with an adult suffering from drug resistant TB and 3 patients (10.3%) were HIV co-infected. Fourteen children (41.2 %) had MDR TB, 11 (32.4 %) had Partial XDR, 1 each (2.9 %) had polyresistant TB and XDR TB. Clinical features of DR-TB are similar in all age groups. Past history of TB with treatment with antitubercular agents and contact with adults suffering with drug-resistant TB are important risk factors in development of drug-resistant - TB in children.

Suárez et al<sup>14</sup> found that out of 234 admitted cases, majority (48.00%) were between 18-50 years. Males were predominant (58.12%). Most patients (61.96%) were underweight (BMI). Among the patients, HIV seropositivity and MDR-TB was found in 8.97% each. A very high default rate was present (20.51%) and a cure rate of 43.59%. The commonest associated co morbidity was Diabetes Mellitus (20.94%). Most patients had moderately extensive (52.99%) lesions in chest x-ray. Relapse of previous antituberculosis treatment was found to be major contributor of MDR-TB suspect as 96.58% had taken ATT previously. Early diagnosis of drug resistance, quality DOTS services and rational use of anti-TB drugs can prevent emerging of MDR-TB as a major public health problem. Adequate dose, adequate duration and Adequate Regimen are the key to success in the treatment of Tuberculosis and prevention of drug Resistance.

## CONCLUSION

Authors found that common clinical features were fever, cough, loss of appetite and loss of weight.

## REFERENCES

1. Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, Paramasivan CN, Narayanan PR, Sahu S, Parmar M, Chadha S. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. *The International Journal of Tuberculosis and Lung Disease*. 2009 Sep 1;13(9):1154-60.
2. Sharma SK, Mohan A, Kadiravan T. HIV-TB co-infection: epidemiology, diagnosis & management. *Indian J Med Res*. 2005 Apr 1;121(4):550-67.
3. World Health Organization, editor. *Global tuberculosis report 2013*. World Health Organization; 2013.
4. National Tuberculosis Association. *Diagnostic standards and classification of tuberculosis*. 1969.

5. Dholakia YN, Shah DP. Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program. *Lung India: official organ of Indian Chest Society*. 2013 Oct;30(4):316.
6. Udawadia ZF, Moharil G. Multidrug-resistant tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. *Lung India: official organ of Indian Chest Society*. 2014 Oct;31(4):336.
7. Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, Manzoor A, Wani MA, u Din S, Thakur N. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. *The Journal of Infection in Developing Countries*. 2009 Nov 21;4(01):19-23.
8. Gupta S, Bandyopadhyay D, Sadhukhan S, Banerjee S. A sociodemographic study of multidrug resistant tuberculosis cases from DOTS clinics of Kolkata. *Journal of the Indian Medical Association*. 2012 Oct;110(10):723-5.
9. Azhar GS. DOTS for TB relapse in India: A systematic review. *Lung India: official organ of Indian Chest Society*. 2012 Apr;29(2):147.
10. Sethi S, Mewara A, Dhatwalia SK, Singh H, Yadav R, Singh K, Gupta D, Wanchu A, Sharma M. Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India. *BMC infectious diseases*. 2013 Dec;13(1):137.
11. Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, Puri MM, Visalakshi P, Behera D. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. *The International Journal of Tuberculosis and Lung Disease*. 2009 Aug 1; 13(8): 976-81.
12. Prasad R, Verma SK, Sahai S, Kumar S, Jain A. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. *Indian Journal of Chest Diseases and Allied Sciences*. 2006 Jul 10;48(3):183.
13. Shah I, Chilkar S. Clinical profile of drug resistant tuberculosis in children. *Indian pediatrics*. 2012 Sep;49(9):741-4.
14. Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G, Bonilla C, Sabogal I, Aranda I, Dye C, Raviglione M. Feasibility and costeffectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. *The Lancet*. 2002 Jun 8;359(9322):1980-9.

**Copyright:** © the author(s) and publisher IJM RP. This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite the article:** Sanjay N. Murudkar, Ramesh Yeshwant Wagh. Assessment of Clinical Profile of Multi Drug Resistant Tuberculosis Patients: An Institutional Based Study. *Int J Med Res Prof*. 2015, 1(2); 160-63.